Savara, Inc. (SVRA) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Hold if already holding. Not a fresh buy at $4.97, but acceptable to hold if already in. Reason: Market cap $0.97B below $1B minimum.
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the... Read more
Hold if already holding. Not a fresh buy at $4.97, but acceptable to hold if already in. Reason: Market cap $0.97B below $1B minimum. Chart setup: RSI 42 mid-range, Bollinger mid-band. Market cap $0.97B below $1B minimum. Not in investable universe. Score 4.8/10, moderate confidence.
Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 85d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Recent Developments — Savara, Inc.
Latest news
- Savara Presents New Biomarker Data From Double-Blind Period Of IMPALA-2 Phase 3 Clinical Trial Evaluating Molgramostim F — benzinga May 20, 2026
- Savara Presents New Exercise Capacity Data From Double-Blind Period Of IMPALA-2 Phase 3 Clinical Trial Evaluating Molgra — benzinga May 18, 2026
- Savara Q1 EPS $(0.15) Misses $(0.14) Estimate — benzinga May 12, 2026 negative
- Savara Announces FDA Extends Review Period For Molgramostim Inhalation Solution Biologics License Application In Autoimm — benzinga Apr 15, 2026 negative
Generated 2026-05-20T20:21:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
4 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $4.97, but acceptable to hold if already in. Reason: Market cap $0.97B below $1B minimum. Chart setup: RSI 42 mid-range, Bollinger mid-band. Market cap $0.97B below $1B minimum. Not in investable universe. Target $9.41 (+89.3%), stop $4.63 (−7.3%), A.R:R 8.4:1. Score 4.8/10, moderate confidence.
Take-profit target: $9.41 (+89.0% upside). Target $9.41 (+89.3%), stop $4.63 (−7.3%), A.R:R 8.4:1. Stop-loss: $4.63.
Market cap $0.97B below $1B minimum.
Savara, Inc. trades at a P/E of N/A (forward -13.0). TrendMatrix value score: 9.0/10. Verdict: Hold.
14 analysts cover SVRA with a consensus score of 4.3/5. Average price target: $11.
What does Savara, Inc. do?Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The...
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Langhorne, Pennsylvania.